Experimental drug offered as last hope for rare cancer patients
NCT ID NCT07502716
Summary
This program provides special access to an experimental drug called ubamatamab for patients with two rare and aggressive cancers: renal medullary carcinoma and epithelioid sarcoma. It is designed for individuals who have exhausted all standard treatment options and cannot join regular clinical trials. Access is granted on a case-by-case basis through a special application process.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIOID SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.